跳至內容

莫塞替諾特

維基百科,自由的百科全書
莫塞替諾特
IUPAC名
N-(2-Aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide
識別
CAS號 726169-73-9  checkY
PubChem 9865515
ChemSpider 8041206
SMILES
 
  • C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4
InChI
 
  • 1/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
InChIKey HRNLUBSXIHFDHP-UHFFFAOYAW
ChEBI 197437
KEGG D09641
IUPHAR配體 7008
性質
化學式 C23H20N6O
摩爾質量 396.44 g·mol−1
若非註明,所有數據均出自標準狀態(25 ℃,100 kPa)下。

莫塞替諾特(英語:Mocetinostat,開發代號:MGCD0103)是一種含氮有機化合物,分子式C23H20N6O,屬於苯甲酰胺組織蛋白去乙醯酶抑制劑[1][2][3]

參考文獻

[編輯]
  1. ^ Pharmion Corporation Release Clinical Data On Oncology HDAC Inhibitor MGCD0103 Presented At The American Society of Clinical Oncology 42nd Annual. BioSpace. 2006-06-06 [2025-01-31]. (原始內容存檔於2011-07-16). 
  2. ^ Gelmon, K.; Tolcher, A.; Carducci, M.; Reid, G. K.; Li, Z.; Kalita, A.; Callejas, V.; Longstreth, J.; Besterman, J. M.; Siu, L. L. Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 2005-06, 23 (16_suppl): 3147. ISSN 0732-183X. doi:10.1200/jco.2005.23.16_suppl.3147 (英語). 
  3. ^ MethylGene to Resume Development of its HDAC Inhibitor, MGCD0103 (Mocetinostat). Earth Times. [2025-01-31].